Highlight Capital

Viva Biotech Holdings is a Shanghai-based company that specializes in structure-based drug discovery services for biotechnology and pharmaceutical clients worldwide. Founded in 2008, the company offers a comprehensive range of research and development services, including fragment-based drug discovery and advanced screening technologies such as affinity selection mass spectrometry and cryo-electron microscopy. Viva Biotech provides various products, including cell lines, crystal structures, GPCR proteins, and antibodies, alongside services in medicinal chemistry, in vitro pharmacology, and antibody discovery. The company operates as an integrated drug discovery platform, combining its expertise in early-stage drug research with contract development and manufacturing services for small molecule active pharmaceutical ingredients and intermediates. Its innovative approach and advanced technological platforms position Viva Biotech as a valuable partner in the global drug development landscape.

Silicon Innovation is a technology company based in Chengdu, China, specializing in interconnect chip solutions for the enterprise sector. Established in December 2019, the company focuses on the development of high-end analog and digital-analog hybrid chips, which cater to various applications including clocks, interfaces, and power management. Silicon Innovation's products support critical industries such as data centers, 5G communications, artificial intelligence, autonomous driving, intelligent monitoring, new energy vehicles, and the Internet of Things. By providing advanced chip solutions, the company enables businesses to enhance their systems and products across multiple sectors.

MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.

Thousand Oaks Biopharmaceuticals, Inc., established in 2017 and headquartered in Haimen, China, specializes in contract development and manufacturing services for the biotechnology industry. The company focuses on developing technologies to produce protein and vaccine compounds, offering integrated control solutions that optimize processes, increase protein expression, and reduce production scale. Thousand Oaks provides personalized, chemically defined cell culture media, formula production, technical support, and ancillary services to its clients in the biopharmaceutical sector.

ColorTech Bio researches and develops precision molecular diagnostic equipment. It offers medical devices to improve biotechnology services and solutions. ColorTech Bio was founded in 2018 and is based in Suzhou, China.

Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

Artivila Therapeutics is a pharmaceutical company established in 2018 and based in Shenzhen, China. The company specializes in biotechnology and is dedicated to improving patient outcomes through innovative drug discovery. Utilizing an AI-powered platform, Artivila focuses on developing new therapeutic solutions for neurodegenerative diseases, cancers, and autoimmune diseases. Its integrated approach aims to consistently and efficiently deliver first-in-class drug candidates, positioning Artivila at the forefront of pharmaceutical research and development.

Biotheus Inc. is a biotechnology company based in Zhuhai, China, established in 2018. The company specializes in the development of monoclonal antibodies, recombinant proteins, and peptide biopharmaceuticals, with a focus on treating malignant tumors and autoimmune diseases. Biotheus is dedicated to advancing innovative biologics through the discovery and commercialization of next-generation multispecific antibodies. Its research emphasizes the mechanisms of regulatory T cells and innate immunity, aiming to create more effective immunotherapy solutions for cancer and metabolic disorders.

Novast Holdings Ltd. is a multinational pharmaceutical company with operations in China and the United States, specializing in the research, development, and manufacture of FDA-inspected generic drugs. The company focuses on creating complex formulations that incorporate challenging active pharmaceutical ingredients (APIs) and offers product development services leveraging its expertise in novel technologies and drug delivery systems. Novast has established itself as a prominent player in the pharmaceutical industry in China, possessing unique capabilities in drug development, quality systems, and infrastructure. It collaborates with pharmaceutical and biotechnology companies to bring products to regulated markets, particularly the U.S. market, where it is recognized as a pioneer among Chinese companies selling pharmaceuticals locally. Novast also operates cGMP manufacturing facilities and has a management team experienced in securing numerous generic drug patents in the U.S., alongside independent research and development of innovative drug-delivery technologies.

Xingyun Group specializes in transforming the digital supply chain for consumer goods, offering comprehensive Direct-to-Consumer (DTC) services. The company employs whole-process SaaS tools to enhance the global commodity trade environment. Its Management Middle-end System Services Engine integrates industrial ecological resources, facilitating cost reduction and efficiency improvements through data utilization. Xingyun Group supports overseas consumer brands in entering the Chinese market while assisting Chinese brands in their global expansion efforts. The platform boasts nearly 160 cooperative and self-operated warehouses across 72 countries and one region, catering to over 350,000 online and offline retailers in China. Its product offerings include maternal and child supplies, beauty care, healthcare, digital products, clothing, and shoes, ensuring reliable and cost-effective purchasing solutions for domestic retailers.

Novast Holdings Ltd. is a multinational pharmaceutical company with operations in China and the United States, specializing in the research, development, and manufacture of FDA-inspected generic drugs. The company focuses on creating complex formulations that incorporate challenging active pharmaceutical ingredients (APIs) and offers product development services leveraging its expertise in novel technologies and drug delivery systems. Novast has established itself as a prominent player in the pharmaceutical industry in China, possessing unique capabilities in drug development, quality systems, and infrastructure. It collaborates with pharmaceutical and biotechnology companies to bring products to regulated markets, particularly the U.S. market, where it is recognized as a pioneer among Chinese companies selling pharmaceuticals locally. Novast also operates cGMP manufacturing facilities and has a management team experienced in securing numerous generic drug patents in the U.S., alongside independent research and development of innovative drug-delivery technologies.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

EnnovaBio is a Chinese pharmaceutical company that specializes in the development of targeted therapeutic drugs. The company focuses on creating innovative immunotherapy pharmaceuticals aimed at treating prevalent autoimmune diseases and brain glioma. By concentrating on both cancer and autoimmune conditions, EnnovaBio seeks to provide effective treatment options that enhance patient outcomes and support medical practitioners in their efforts to address complex health challenges. Through its research and development initiatives, EnnovaBio aims to advance the field of immunotherapy and contribute to improved healthcare solutions in China.

Genetron Health is a leading precision medicine company specializing in oncology, with a strong focus on cancer molecular profiling. The company leverages advanced technologies in molecular biology and data science to enhance cancer treatment. Genetron Health offers comprehensive health management products covering all aspects of full-cycle cancer clinical treatment, including risk assessment, early screening, molecular pathology diagnosis, medication guidance, and prognosis monitoring. They provide reliable molecular clinical services and professional cancer genetic risk assessments for patients and high-risk individuals. With global genomics sequencing and bioinformatics platforms, research and development centers in North Carolina and Beijing, and clinical laboratories across major Chinese cities, Genetron Health aims to expand its sales network throughout China. The company is dedicated to serving both Chinese and global cancer patients with its expertise in cancer genomics and efficient clinical translation.

Suzhou Kintor Pharmaceuticals is a biopharmaceutical company established in 2009, primarily engaged in the research and development of innovative drugs targeting various cancers and androgen receptor-related diseases. Headquartered in Suzhou, China, the company focuses on addressing significant unmet medical needs in conditions such as metastatic castration-resistant prostate cancer, breast cancer, and liver cancer, which collectively represent a substantial portion of the global cancer burden. Kintor's leading drug candidates include Proxalutamide, currently undergoing clinical trials for prostate and breast cancer, and Pyrilutamide, which targets androgenetic alopecia and acne vulgaris. The company also develops several other drug candidates, including ALK-1 for liver cancer and Detorsertib, a second-generation mTOR inhibitor for metastatic solid tumors. Kintor's extensive product pipeline is built on proprietary research and development, aiming to deliver both “best-in-class” and “first-in-class” therapeutic options to patients in need.

Julikang is a third-party medical device disinfection service provider focused on the healthcare industry in China. The company offers disinfection services to numerous hospitals, utilizing automated cleaning devices to ensure thorough sanitation of items and areas. By interfacing with hospital information systems, Julikang implements sterile item traceability management software, which enhances the management of sterile articles. This integration allows real-time access to physical parameter information of medical devices, ensuring efficient traceability and compliance with hygiene standards. Through its services, Julikang aims to deliver professional quality sterilization and disinfection solutions to healthcare enterprises.

Angstrom STEM is a brand of Anglia Education Group, integrating the resources and achievements of science and technology education of Shanghai Jiaotong University, and introducing the technology experience model of the United States and Canada, innovatively opening up STEM entertainment and education, integrating scientific experiments, model construction, mechanical energy, robot construction With programming, 3D printing, mathematics, etc., and focusing on the application and innovation of the latest science and technology, we have established a complete scientific STEM curriculum system to promote the quality education of domestic children and build a leading high-end STEM education brand in China.

Boholo, founded in 2011 and based in Shanghai, China, offers a digital medical management solution that integrates various advanced technologies. Its platform includes services such as clinical case management, three-dimensional surgical modeling and planning, and a multimedia case database. By utilizing artificial intelligence and machine vision, Boholo's medical imaging tools generate precise 3D anatomical models that assist medical professionals in planning surgical procedures, thereby increasing the likelihood of successful outcomes. The company also provides a comprehensive service platform that facilitates communication among specialists worldwide, enhancing their ability to deliver quality care.

BrightGene Bio-Medical Technology Company is a biopharmaceutical firm based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of innovative medicines and high-quality generic active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The company has a diverse product pipeline that includes immuno-oncological agents, GLP-1 receptor agonists for type 2 diabetes, and antibody-drug conjugates aimed at treating solid tumors and brain cancers. Additionally, BrightGene develops a variety of treatments such as Eribulin, Trabectedin, and various macromolecules and cytotoxic payloads. Its product offerings span multiple therapeutic areas, including oncology, cardiology, infectious diseases, and immunology. Founded in 2001, BrightGene has positioned itself as a leader in small molecules and nucleotide drugs, focusing on advancing therapeutics across all stages of development.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

VCBeat is an online platform founded in 2014 and headquartered in Chongqing, China, that focuses on delivering news and industry research specifically within the healthcare sector. The company provides comprehensive media coverage, data, and resources aimed at healthcare professionals, investors, and the general public. Through its service platform, VCBeat offers brand communication and industry consulting services, supporting healthcare entrepreneurs with industry research and the integration of various industry resources. By focusing on the future development of the healthcare industry, VCBeat plays a vital role in disseminating critical information and insights to its audience.

Biotheus Inc. is a biotechnology company based in Zhuhai, China, established in 2018. The company specializes in the development of monoclonal antibodies, recombinant proteins, and peptide biopharmaceuticals, with a focus on treating malignant tumors and autoimmune diseases. Biotheus is dedicated to advancing innovative biologics through the discovery and commercialization of next-generation multispecific antibodies. Its research emphasizes the mechanisms of regulatory T cells and innate immunity, aiming to create more effective immunotherapy solutions for cancer and metabolic disorders.

Predicine Huidu Medical Technology Co., Ltd. is located in Fengxian, China, and specializes in the research and development of innovative technologies in the healthcare sector. The company focuses on gene detection methods and bioinformatics algorithms specifically designed for cancer diagnosis and monitoring. By creating a clinical application platform, Predicine Huidu Medical Technology connects patients with healthcare companies, facilitating advancements in tumor diagnosis and treatment. Through its technological offerings, the company aims to enhance the accuracy and effectiveness of cancer care.

Chemclin Biotech is a Chinese technical service provider specializing in in-vitro diagnostic instruments and auxiliary reagents for clinical diagnosis. The company develops, produces, and sells clinical immunochemiluminescence diagnostic testing reagents and instruments. Its services encompass a range of clinical inspection instruments, including chemiluminescence and biochemical reagents, as well as technical support, management, and certification. Additionally, Chemclin operates independent medical laboratories and is focused on introducing innovative diagnostic products and services to the Chinese market.

Chowsing Live is an online retailer based in Shanghai, China, specializing in pet products and accessories. The company offers a range of items, including pet jumbo wipes, cat collars with bells, and flushable cat litters. Chowsing Live focuses on promoting design and creativity in its product development, aiming to address the genuine needs of pets and their owners. By providing innovative solutions, the company strives to foster a natural and harmonious lifestyle for both pets and pet-raising families.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Junhetang operates a network of traditional Chinese medicine (TCM) clinics, providing a range of healthcare services that include herbal medicine, acupuncture, massage, exercise, and dietary therapies. The company combines TCM culture with the expertise of renowned TCM practitioners to deliver personalized medical services. Additionally, Junhetang integrates modern internet services into its offerings, creating an innovative TCM service network that encompasses education, training, medical care, and health maintenance. Headquartered in Nanjing, the company is actively expanding its presence in several major cities across China, including Shanghai, Shenzhen, Chengdu, and Taiyuan.

Suzhou Kintor Pharmaceuticals is a biopharmaceutical company established in 2009, primarily engaged in the research and development of innovative drugs targeting various cancers and androgen receptor-related diseases. Headquartered in Suzhou, China, the company focuses on addressing significant unmet medical needs in conditions such as metastatic castration-resistant prostate cancer, breast cancer, and liver cancer, which collectively represent a substantial portion of the global cancer burden. Kintor's leading drug candidates include Proxalutamide, currently undergoing clinical trials for prostate and breast cancer, and Pyrilutamide, which targets androgenetic alopecia and acne vulgaris. The company also develops several other drug candidates, including ALK-1 for liver cancer and Detorsertib, a second-generation mTOR inhibitor for metastatic solid tumors. Kintor's extensive product pipeline is built on proprietary research and development, aiming to deliver both “best-in-class” and “first-in-class” therapeutic options to patients in need.

Sansure Biotech Inc. is a biotechnology company based in Changsha, Hunan Province, established in 2008. The company specializes in molecular diagnosis and genetic testing, developing and manufacturing a range of products that include nucleic acid extraction kits, real-time polymerase chain reaction (PCR) diagnostic kits, and fluorescence systems. Its product portfolio encompasses diagnostic kits for various health concerns, including novel coronavirus detection, viral hepatitis, AIDS, cancer biomarkers, and respiratory, digestive, and genetic diseases. Additionally, Sansure Biotech provides instruments and consumables to support its diagnostic offerings. The company primarily serves hospitals and laboratories both in China and internationally, focusing on enhancing diagnostic capabilities across multiple medical fields.

EnnovaBio is a Chinese pharmaceutical company that specializes in the development of targeted therapeutic drugs. The company focuses on creating innovative immunotherapy pharmaceuticals aimed at treating prevalent autoimmune diseases and brain glioma. By concentrating on both cancer and autoimmune conditions, EnnovaBio seeks to provide effective treatment options that enhance patient outcomes and support medical practitioners in their efforts to address complex health challenges. Through its research and development initiatives, EnnovaBio aims to advance the field of immunotherapy and contribute to improved healthcare solutions in China.

General Healthy specializes in pharmaceutical logistics automation and mobile medical solutions. Based in Shanghai, the company offers products and services designed for the intelligent management of medicines, catering to both medical services and the pharmaceutical circulation industries. Through its innovative approach, General Healthy aims to enhance the efficiency and effectiveness of medicine management, addressing the needs of healthcare providers and pharmaceutical distributors.

Rundong Pharmaceutical R&D is a contract research organization (CRO) that focuses on clinical research outsourcing for pharmaceutical and biotechnology companies. It offers a comprehensive range of services, including clinical operations, medical data management, biostatistics, and medical project management. As a key player in the industry, Rundong is the main initiator and promoter of the China CRO Alliance, highlighting its leadership role in the field. The company has also achieved the distinction of being the first CRO in China to receive ISO 9001:2008 quality management system certification, demonstrating its commitment to high-quality standards in clinical research. Through its professional services, Rundong aims to support various companies in the pharmaceutical and biotech sectors in advancing their medical research initiatives.

Kontour Medical is a company based in Xi'an, China, specializing in the research and development, production, and sale of medical devices for various surgical fields, including neurosurgery, cardiovascular surgery, craniofacial surgery, and stomatology. Founded in 2005, the company offers a diverse range of products, including titanium mesh and PEEK cranial fixation systems for neurosurgery, sternum and rib fixation systems for thoracic surgery, and interbody fusion cages for neurospine applications. Additionally, Kontour Medical provides oral implant systems featuring titanium and titanium alloy dental implants, along with other surgical products such as hernia repair patches and lamina plates. Through its commitment to innovation and quality, Kontour Medical aims to enhance surgical outcomes and patient care in the medical device industry.

Genechem (China), officially known as Shanghai Genechem Co., Ltd., is a high-tech enterprise located in the Shanghai Zhangjiang Hi-Tech Park. The company specializes in providing research and development services focused on life science solutions that support gene research. It integrates various functions including genetic technology services, technological transformation, product development, and sales. Through its comprehensive offerings, Genechem aims to advance the field of genetics and contribute to innovations within the life sciences sector.

Zylox Medical Device Co., founded in 2012 in Hangzhou, is a specialized company focused on developing innovative medical devices for interventional procedures. Established by a team of experienced professionals with backgrounds in top-tier medical device manufacturers, Zylox offers a diverse range of products primarily aimed at peripheral vascular and neurovascular interventions. Its product line includes various devices such as PTA balloons, drug-coated PTA balloons, superficial femoral artery (SFA) stents, and the Thrombite Clot Retriever Device. Zylox is committed to improving patient outcomes by consistently enhancing its cutting-edge medical technologies and ensuring the highest quality standards.

Quyi Network is a technology company based in China that specializes in providing a service platform for medical assistance. The platform facilitates online services such as booking appointments with doctors, accessing lab test results, and processing payments. By offering these features, Quyi Network enables users to obtain timely medical advice and information, enhancing the overall healthcare experience.

Suzhou Kintor Pharmaceuticals is a biopharmaceutical company established in 2009, primarily engaged in the research and development of innovative drugs targeting various cancers and androgen receptor-related diseases. Headquartered in Suzhou, China, the company focuses on addressing significant unmet medical needs in conditions such as metastatic castration-resistant prostate cancer, breast cancer, and liver cancer, which collectively represent a substantial portion of the global cancer burden. Kintor's leading drug candidates include Proxalutamide, currently undergoing clinical trials for prostate and breast cancer, and Pyrilutamide, which targets androgenetic alopecia and acne vulgaris. The company also develops several other drug candidates, including ALK-1 for liver cancer and Detorsertib, a second-generation mTOR inhibitor for metastatic solid tumors. Kintor's extensive product pipeline is built on proprietary research and development, aiming to deliver both “best-in-class” and “first-in-class” therapeutic options to patients in need.